Vincerx Pharma's (VINC) "Overweight" Rating Reaffirmed at Ca

Vincerx Pharma's (VINC) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Vincerx Pharma (NASDAQ:VINC – Free Report) in a report released on Tuesday morning, Benzinga reports. Vincerx Pharma Price Performance VINC opened at $1.00 on Tuesday. Vincerx Pharma has a one year low of $0.61 and a one year high of $9.37. The company’s 50 day simple […]

Related Keywords

United States , Vincerx Pharma , Susquehanna International Group , Walleye Capital , Vincerx Pharma Inc , Cantor Fitzgerald , Vincerx Pharma Company Profile , Goldman Sachs Group Inc , Free Report , International Group , Sachs Group , Point Capital Management , Get Free Report , Vincerx Pharma Daily ,

© 2025 Vimarsana